MPs question cost of an Orkambi compulsory license

Parliamentary Under-Secretary for Health and Social Care Steve Brine said a compulsory license for cystic fibrosis drug Orkambi ivacaftor/lumacaftor could cost NHS England more in the long run than negotiating a deal with Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

The remarks came during a

Read the full 412 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE